Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $80.00 at Needham & Company LLC

Xenon Pharmaceuticals (NASDAQ:XENE) had its target price upped by investment analysts at Needham & Company LLC from $58.00 to $80.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price target points to a potential upside of 31.32% from the company’s previous close.

XENE has been the subject of a number of other reports. Jefferies Financial Group reiterated a “buy” rating and issued a $65.00 target price on shares of Xenon Pharmaceuticals in a report on Monday. Wells Fargo & Company lifted their target price on shares of Xenon Pharmaceuticals from $48.00 to $49.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. Wolfe Research initiated coverage on shares of Xenon Pharmaceuticals in a research note on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price target on the stock. JPMorgan Chase & Co. raised their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Finally, Stifel Nicolaus set a $66.00 price objective on Xenon Pharmaceuticals in a report on Tuesday, February 10th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $57.92.

Xenon Pharmaceuticals Stock Performance

Shares of XENE traded up $18.98 during trading hours on Monday, hitting $60.92. The company had a trading volume of 9,234,438 shares, compared to its average volume of 1,143,636. The stock has a market capitalization of $5.07 billion, a price-to-earnings ratio of -13.97 and a beta of 0.91. Xenon Pharmaceuticals has a 52-week low of $26.74 and a 52-week high of $62.91. The firm has a fifty day moving average price of $42.25 and a 200-day moving average price of $41.24.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter last year, the firm posted ($0.84) earnings per share. Research analysts anticipate that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the sale, the chief executive officer owned 6,000 shares in the company, valued at $266,580. The trade was a 86.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 4.07% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd acquired a new stake in Xenon Pharmaceuticals in the 4th quarter valued at about $55,000. Corient Private Wealth LLC acquired a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at $1,125,000. Mackenzie Financial Corp acquired a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $210,000. ADAR1 Capital Management LLC increased its stake in shares of Xenon Pharmaceuticals by 7.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 203,969 shares of the biopharmaceutical company’s stock valued at $9,142,000 after buying an additional 14,871 shares during the period. Finally, XTX Topco Ltd bought a new stake in Xenon Pharmaceuticals in the 4th quarter valued at about $964,000. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals News Roundup

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Company release — Xenon announced positive topline results from the Phase 3 X‑TOLE2 study of azetukalner in focal‑onset seizures, reporting the trial met its primary endpoint and supporting the drug’s efficacy. GlobeNewswire: Topline Data
• Positive Sentiment: Major press coverage & market reaction — Multiple outlets reported the strong Phase 3 readout and noted a sharp stock rally and volume surge as investors reacted to the efficacy data. Blockonomi: Stock Rockets
• Positive Sentiment: Regulatory path indicated — Company commentary and analyst notes point to an intended NDA submission target in Q3 2026 and plans to pursue epilepsy plus additional neuropsychiatric indications, creating a near‑term catalyst runway. Seeking Alpha: NDA timing & pipeline
• Neutral Sentiment: Trading mechanics — Nasdaq briefly halted XENE trading for “news pending” ahead of the announcement, a typical market response to major clinical readouts that can amplify short‑term volatility. (Market bulletin noted halt at 06:55 AM ET.)
• Negative Sentiment: Valuation and risk concerns — Independent analysts flag that the post‑readout rally may price in aggressive uptake; they also warn of a crowded anti‑seizure market, notable adverse‑event rates called out in commentary, and commercial execution risks that could temper longer‑term returns. Seeking Alpha: Valuation & risks

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.